Market closedNon-fractional
Cabaletta Bio/CABA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cabaletta Bio
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Ticker
CABA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Philadelphia, United States
Employees
119
Website
www.cabalettabio.com
Cabaletta Bio Metrics
BasicAdvanced
$326M
Market cap
-
P/E ratio
-$1.73
EPS
2.47
Beta
-
Dividend rate
Price and volume
Market cap
$326M
Beta
2.47
Financial strength
Current ratio
12.657
Quick ratio
12.455
Long term debt to equity
0.345
Total debt to equity
3.684
Management effectiveness
Return on assets (TTM)
-31.16%
Return on equity (TTM)
-49.06%
Valuation
Price to book
1.48
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
-4.544
Growth
Earnings per share change (TTM)
-4.11%
3-year earnings per share growth (CAGR)
4.42%
What the Analysts think about Cabaletta Bio
Analyst Ratings
Majority rating from 11 analysts.
Cabaletta Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
20.19%
Profit margin
0.00%
NaN%
Cabaletta Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.37
-$0.46
-$0.51
-
Expected
-$0.44
-$0.40
-$0.39
-$0.48
-$0.55
Surprise
-16.38%
-8.33%
17.23%
7.23%
-
Cabaletta Bio News
AllArticlesVideos
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
GlobeNewsWire·4 weeks ago
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Seeking Alpha·4 weeks ago
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cabaletta Bio stock?
Cabaletta Bio (CABA) has a market cap of $326M as of July 27, 2024.
What is the P/E ratio for Cabaletta Bio stock?
The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of July 27, 2024.
Does Cabaletta Bio stock pay dividends?
No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cabaletta Bio dividend payment date?
Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cabaletta Bio?
Cabaletta Bio (CABA) has a beta rating of 2.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cabaletta Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.